MEDLINE was searched from 1989 to 1992, using the search terms 'bacterial vaginosis', 'non-specific vaginosis', 'clindamycin', 'metronidazole'. Searches of books on sexually transmitted diseases (STDs), abstracts of meetings were gatherered, and information from drug manufacturers sought. Other recent reviews were investigated.
How were differences between studies investigated?
The authors do not state how differences between the studies were investigated.
Results of the review
The number of studies included is unclear as studies were combined with those included in an earlier review (Lossick 1990 ).
Narrative summary of 5 studies of systemic formulations, 8 studies of topical formulations, 3 studies of treatment of sex partners, 1 study of treatment during pregnancy, 1 study of treatment for asymptomatic patients during surgery.
Systemic formulations: cure rates for the systemic metronidazole treatment range from 70% to 100% for individual studies, with a 'cumulative' cure rate of 92% (295 out of 322 patients treated) for the 7-day treatment regimen and 87% (369 out of 426) for the single dose regimen. The relapse rate for the individual studies ranged from 13%-44% for the 7-day regimen and 0-53% for the single dose.
Topical formulations: evidence of the efficacy of metronidazole sponges suggests 3-day sponge to be more efficacious than the 1-day sponge. The high dose (1000mg) 3-day sponge was found to have a better cure rate than the lower dose (250mg ) 3-day sponge (88% vs 56%). The efficacy of metronidazole pessaries is less clear. The only RCT evaluating this treatment found a high cure rate at one week (41 out of 41) but the study suffered from a high drop-out rate and 7 out of 41 women experienced local side-effects (itching, burning or increased vaginal discharge).
Treatment of sexual partners: one study reported a significantly different cure rate between women whose steady partners were treated with metronidazole compared to a placebo. The remaining studies found no effect. The authors conclude that the 'best' data show no benefit. Treatment during pregnancy: as metronidazole is contraindicated during the first trimester of pregnancy, clindamycin is the preferred treatment during pregnancy. The one study evaluating the effects of clindamycin therapy found the treatment to be safe and well-tolerated.
Treatment before surgical abortion: one RCT found a threefold reduction in the incidence of post-abortion pelvic inflammatory disease (PID)in women with BV treated with metronidazole.
Treatment of asymtomatic patients during surgery: only one RCT was identified which suggests that treatment of asymptomatic patients with BV be considered before performing surgical abortion procedures to prevent PID.
